Tamiflu U.S. Labeling Adopts Japanese Warnings
This article was originally published in PharmAsia News
Executive Summary
A spike in the number of postmarketing adverse event reports associated with Tamiflu use is prompting FDA staff to recommend adoption of international labeling for the antiviral
You may also be interested in...
Roche Tamiflu “Re-Launch” Seeks To Bolster Seasonal Demand
Market research found that unprompted awareness of the antiviral was low, despite having strong publicity for use in pandemic preparedness.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).